WALTHAM, Mass. — September 2, 2025 — Leads & Copy — Upstream Bio, Inc. (Nasdaq: UPB) announced positive top-line results from its Phase 2 VIBRANT trial of verekitug for chronic rhinosinusitis with nasal polyps (CRSwNP). The trial met its primary endpoint, showing a significant reduction in endoscopic nasal polyp score (NPS). Key secondary endpoints, including nasal congestion score (NCS) and need for surgery or systemic corticosteroids, also showed significant improvements.
The 24-week study revealed that verekitug, dosed every 12 weeks, led to a statistically significant and clinically meaningful reduction from baseline in placebo-adjusted endoscopic NPS of -1.8 (p<0.0001). A reduction of -0.8 (p=0.0003) was seen in nasal congestion score, and a 76% (p=0.03) reduction in the need for surgery or systemic corticosteroids.
The trial included 81 adults with CRSwNP. Verekitug was generally well tolerated, with no serious adverse events observed. Upstream Bio plans to present further details from the VIBRANT trial at an upcoming medical conference.
Aaron Deykin, MD, Chief Medical Officer and Head of Research & Development at Upstream Bio, commented on the results, noting their potential to advance the standard of care in CRSwNP treatment.
Rand Sutherland, MD, Chief Executive Officer of Upstream Bio, highlighted verekitug’s potential as an addition to existing biologic options for CRSwNP treatment.
Joseph Han, MD, Professor at Old Dominion University (Eastern Virginia Medical School) and principal investigator, emphasized the improvements observed with verekitug in nasal polyp reduction and symptom relief.
Meggan Buckwell, Director, Corporate Communications and Investor Relations, ir@upstreambio.com
Source: Upstream Bio
